Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRX NASDAQ:MNKD NASDAQ:XOMA NASDAQ:XOMAO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$7.70-3.3%$8.32$6.01▼$11.31$1.62B1.132.31 million shs6.62 million shsMNKDMannKind$5.43-3.2%$4.36$3.38▼$7.63$1.67B1.025.83 million shs4.72 million shsXOMAXOMA Royalty$36.70-2.4%$30.91$18.35▼$38.45$443.63M0.9950,305 shs125,719 shsXOMAOXOMA$25.68$25.48$23.32▼$25.87N/AN/A2,862 shs901 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals0.00%-2.65%-8.11%-23.76%-3.27%MNKDMannKind0.00%-2.51%+37.82%+44.03%-18.47%XOMAXOMA Royalty0.00%-1.92%+12.06%+52.60%+28.05%XOMAOXOMA0.00%+0.67%+0.43%+1.74%+1.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$7.70-3.3%$8.32$6.01▼$11.31$1.62B1.132.31 million shs6.62 million shsMNKDMannKind$5.43-3.2%$4.36$3.38▼$7.63$1.67B1.025.83 million shs4.72 million shsXOMAXOMA Royalty$36.70-2.4%$30.91$18.35▼$38.45$443.63M0.9950,305 shs125,719 shsXOMAOXOMA$25.68$25.48$23.32▼$25.87N/AN/A2,862 shs901 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals0.00%-2.65%-8.11%-23.76%-3.27%MNKDMannKind0.00%-2.51%+37.82%+44.03%-18.47%XOMAXOMA Royalty0.00%-1.92%+12.06%+52.60%+28.05%XOMAOXOMA0.00%+0.67%+0.43%+1.74%+1.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.90Moderate Buy$16.70116.88% UpsideMNKDMannKind 3.17Buy$11.17105.65% UpsideXOMAXOMA Royalty 3.33Buy$69.5089.37% UpsideXOMAOXOMA 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest XOMA, XOMAO, MNKD, and BCRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/18/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.009/10/2025XOMAXOMA RoyaltyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/5/2025MNKDMannKindOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$12.00 ➝ $15.009/3/2025MNKDMannKindWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$9.00 ➝ $10.009/2/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $11.008/26/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $8.008/25/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.008/12/2025XOMAXOMA RoyaltyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/7/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$8.00 ➝ $7.008/4/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.007/23/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$10.00 ➝ $8.00(Data available from 9/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$450.71M3.59N/AN/A($2.30) per share-3.35MNKDMannKind$285.50M5.84$0.14 per share39.13($0.29) per share-18.72XOMAXOMA Royalty$12.77M34.73N/AN/A$6.95 per share5.28XOMAOXOMA$12.77MN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals-$88.88M-$0.18N/AN/A1.55-6.41%N/A-1.78%11/3/2025 (Estimated)MNKDMannKind$27.59M$0.1149.3723.61N/A10.87%-32.60%7.81%11/6/2025 (Estimated)XOMAXOMA Royalty-$13.82M-$1.55N/AN/AN/A-27.57%2.63%0.97%11/6/2025 (Estimated)XOMAOXOMAN/AN/A0.00∞N/AN/AN/AN/A11/5/2025 (Estimated)Latest XOMA, XOMAO, MNKD, and BCRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025XOMAXOMA Royalty-$0.12$0.48+$0.60$0.44$9.39 million$13.13 million8/6/2025Q2 2025MNKDMannKind$0.04$0.05+$0.01N/A$77.82 million$76.53 million8/4/2025Q2 2025BCRXBioCryst Pharmaceuticals$0.03$0.15+$0.12$0.02$149.59 million$163.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/AXOMAXOMA RoyaltyN/AN/AN/AN/AN/AXOMAOXOMA$2.098.14%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A2.252.22MNKDMannKindN/A2.502.24XOMAXOMA Royalty1.414.884.88XOMAOXOMAN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%MNKDMannKind49.55%XOMAXOMA Royalty95.92%XOMAOXOMAN/AInsider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals5.10%MNKDMannKind2.70%XOMAXOMA Royalty9.10%XOMAOXOMAN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530209.92 million199.21 millionOptionableMNKDMannKind400306.83 million298.54 millionOptionableXOMAXOMA Royalty1012.09 million10.99 millionOptionableXOMAOXOMA10N/AN/ANot OptionableXOMA, XOMAO, MNKD, and BCRX HeadlinesRecent News About These CompaniesShort Interest in XOMA Co. (NASDAQ:XOMAO) Increases By 33.3%September 19 at 2:01 AM | americanbankingnews.comXOMA (NASDAQ:XOMAO) Trading Up 0.3% - Here's What HappenedSeptember 12, 2025 | americanbankingnews.comMural Oncology accepts XOMA takeover bidAugust 21, 2025 | thepharmaletter.comTMural Jumps on Partnership with XOMAAugust 20, 2025 | baystreet.caMural Oncology To Be Acquired By Xoma RoyaltyAugust 20, 2025 | msn.comXOMA Royalty to Buy Mural Oncology for Up to $38.8 MillionAugust 20, 2025 | marketwatch.comXoma adds fading Mural Oncology to portfolio of struggling biotechsAugust 20, 2025 | fiercebiotech.comFXoma reports Q2 EPS 44c, consensus (15c)August 13, 2025 | msn.comXOMA Revenue Jumps 39% in Fiscal Q2August 13, 2025 | aol.comAXOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business AchievementsAugust 13, 2025 | finance.yahoo.comPharmalittle: We’re reading about Bill Gates’ women’s health pledge, a Vertex pain drug failure, and moreAugust 5, 2025 | statnews.comSPromise of gamma delta bispecific antibodies prompts XOMA acquisitionAugust 5, 2025 | thepharmaletter.comTXoma Royalty to Acquire Lava TherapeuticsAugust 4, 2025 | marketwatch.comHillevax Shares Gain on Acquisition Deal with XOMA RoyaltyAugust 4, 2025 | msn.comXoma Royalty to Acquire Lava Therapeutics, End Development of Lead CandidateAugust 4, 2025 | precisionmedicineonline.comPXoma strikes deals to buy struggling biotechs HilleVax, LavaAugust 4, 2025 | finance.yahoo.comXoma Royalty to Acquire HilleVaxAugust 4, 2025 | marketwatch.comXOMA Royalty to acquire cancer drug developer LAVA TherapeuticsAugust 4, 2025 | msn.comXoma Royalty to Acquire Lava Therapeutics -- UpdateAugust 4, 2025 | marketwatch.comXOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last? - NasdaqJune 26, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXOMA, XOMAO, MNKD, and BCRX Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$7.70 -0.26 (-3.27%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$7.78 +0.09 (+1.10%) As of 09/19/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.MannKind NASDAQ:MNKD$5.43 -0.18 (-3.21%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$5.50 +0.07 (+1.20%) As of 09/19/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.XOMA Royalty NASDAQ:XOMA$36.70 -0.89 (-2.37%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$36.47 -0.23 (-0.63%) As of 09/19/2025 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.XOMA NASDAQ:XOMAO$25.68 0.00 (0.00%) Closing price 09/19/2025 03:57 PM EasternExtended Trading$25.68 0.00 (0.00%) As of 09/19/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Berkshire-Backed Lennar Slides After Weak Q3 Earnings Azure Leads While AI Excitement Fuels Microsoft Stock Caterpillar Stock Hits All-Time High—Is There More Room to Run? The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
